OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1061 / 1061
页数：1
相关论文
共 50 条
  • [1] Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue
    Piotrowska, Zofia
    Hata, Aaron N.
    CLINICAL CANCER RESEARCH, 2020, 26 (11) : 2441 - 2443
  • [2] CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Hui, C.
    Wakelee, H. A.
    Neal, J. W.
    Ramchandran, K. J.
    Das, M.
    Nagpal, S.
    Roy, M.
    Huang, J.
    Pollom, E.
    Myall, N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E110 - E110
  • [3] Safety of tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
    Liam, C. K.
    Kim, T. M.
    Yang, J-J.
    Huang, C.
    Voon, P-J.
    Tho, L. M.
    Zhou, Q.
    Wang, J.
    Hayashi, H.
    Tan, D. S. W.
    Danchaivijitr, P.
    Nguyen, V. N.
    Wong, K. H.
    Yang, J. C-H.
    Le, X.
    Ellers-Lenz, B.
    Karachaliou, N.
    Ghori, V.
    Berghoff, K.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1691 - S1691
  • [4] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
  • [5] Tepotinib plus Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul, S.
    Mun, T. L.
    Wang, C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1099 - S1100
  • [6] Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib
    Robinson, N. D.
    Zhan, P.
    Udelsman, B.
    Boffa, D. J.
    Goldberg, S. B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S364 - S364
  • [7] Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics
    de Garibay, G. Ruiz
    Roch, B.
    Garrido Lopez, P.
    Isla, D.
    Aguado, C.
    Callejo Perez, A.
    Marse Fabregat, R.
    Garcia Campelo, M. R.
    Blasco Cordellat, A.
    Sanchez Torres, J. M.
    Bernabe Caro, R.
    Juan Vidal, O. J.
    Carpeno, J. De Castro
    Franco, F. F.
    Ramos Garcia, I.
    Gomez Rueda, A.
    Conde Gallego, E.
    Ponce Aix, S.
    Paz-Ares, L.
    Zugazagoitia, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1015 - S1016
  • [8] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
    Le, Xiuning
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Yang, Jinji
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kim
    Mazieres, Julien
    Lye Mun Tho
    Hayashi, Hidetoshi
    Nguyen Nhung
    Chia, Puey Ling
    De Marinis, Fillippo
    Raskin, Jo
    Zhou, Qinghua
    Finochhiaro, Giovanna
    Tan, Daniel
    Brutlach, Sabine
    O'Brate, Aurora
    Adrian, Svenja
    Berghoff, Karin
    Ellers-Lenz, Barbara
    Karachaliou, Niki
    Wu, Yi-Long
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [9] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [10] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
12345